Skip to main
TOI

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The Oncology Institute Inc is projected to experience significant financial growth as its partnership with Helios is expected to enhance margins in 2026 and 2027, alongside a steady increase in the number of clinics from 67 to 86 from 2022 to 2024. With the U.S. oncology market valued at over $200 billion and anticipated to grow at a compound annual growth rate (CAGR) of over 10%, the company is well-positioned to benefit from trends favoring oncology services and patient care. Continued expansion in key states like Nevada and Florida, coupled with robust revenue growth in the dispensary segment and a focus on fee-for-service transitioning to value-based care, further supports a positive outlook for the company's financial performance.

Bears say

The Oncology Institute Inc. has experienced a significant decline in revenue contributions from key partnerships, with HUM's share of revenue dropping from 20% to less than 10%. The company's gross margins were adversely affected by contract losses in 2024 and subsequent launches that may increase pressure on profitability as they scale. Additionally, TOI is facing challenges such as declining dispensary margins due to the elimination of DIR fees and a revenue growth trend that lags behind the industry average, leading to a complex financial outlook with potential cash covenant concerns.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.